For ERα negative (ERα−), progesterone receptor negative (PR−), and HER2+ (ERα−/PR−/HER2+) breast tumors, a combination of pertuzumab, trastuzumab, and docetaxel has been effective (59). The gene discussed is ESR1; the disease is breast neoplasm.